Literature DB >> 10815855

308-nm excimer laser for the treatment of psoriasis: a dose-response study.

P Asawanonda1, R R Anderson, Y Chang, C R Taylor.   

Abstract

OBJECTIVE: To determine the dose-response relationship of excimer laser-generated 308-nm UV-B radiation for treating psoriasis.
DESIGN: Pilot study with a before-after design.
SETTING: A university dermatology service. PATIENTS: Thirteen consecutive patients with at least 4 large, stable psoriasis plaques.
INTERVENTIONS: Excimer laser-generated 308-nm UV-B radiation was given to each of 4 plaques, which received 1, 2, 4, and 20 treatments, respectively. Untreated areas within each plaque served as controls. Within each plaque, 8 doses based on multiples of a predetermined minimal erythema dose (MED) were tested in distinct sites. The multiples were 0.5 and 1 (low dose); 2, 3, 4, and 6 (medium dose); and 8 and 16 (high dose). At every treatment, the dose for each site remained fixed at the same MED multiple. A psoriasis severity index score was determined for each area before, every 2 weeks during, and 2 and 4 months after treatment.
RESULTS: The mean+/-SD MED was 203.03+/-57.84 mJ/ cm2. Treatment with high fluences produced significantly better results than that with medium and low fluences at weeks 4, 6, 8, and 10 (P<.05). At 4 months' follow-up, all sites that received low or medium fluences had recurrences, whereas those that underwent a single treatment at 8 and 16 MED multiples remained in remission.
CONCLUSIONS: With 308-nm UV-B radiation generated by an excimer laser, it is possible to clear psoriasis with as little as 1 treatment with moderately long remission. In contrast to traditional phototherapy techniques, this handheld excimer laser UV-B therapy is selectively directed toward lesional skin, thus sparing the surrounding normal skin from unnecessary radiation exposure. Treatment of other inflammatory diseases and limited psoriasis seems reasonable to pursue with this modality.

Entities:  

Mesh:

Year:  2000        PMID: 10815855     DOI: 10.1001/archderm.136.5.619

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  18 in total

Review 1.  [The excimer laser in dermatology and esthetic medicine].

Authors:  H Grema; C Raulin
Journal:  Hautarzt       Date:  2004-01       Impact factor: 0.751

2.  [From Einstein's Quantum Theory to modern laser therapy. The history of lasers in dermatology and aesthetic medicine].

Authors:  K Graudenz; C Raulin
Journal:  Hautarzt       Date:  2003-05-15       Impact factor: 0.751

Review 3.  A review of melanin sensor devices.

Authors:  Vangelis George Kanellis
Journal:  Biophys Rev       Date:  2019-08-08

4.  Innovations in Psoriasis Management: Based on Selected Presentations from the Symposium for Cosmetic Advances & Laser Education (SCALE) Virtual Congress-July 24 to 26, 2020.

Authors:  Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2020-11-01

5.  Objective quantification of melasma severity using melanometers to quantify melanin pigmentation.

Authors:  Vangelis George Kanellis
Journal:  Biophys Rev       Date:  2020-09-17

Review 6.  [The 308 nm Excimer laser for the treatment of psoriasis and inflammatory skin diseases].

Authors:  K Fritz; C Salavastru
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

Review 7.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  [Laser surgery in dermatology. Risks and chances].

Authors:  W Kimmig
Journal:  Hautarzt       Date:  2003-05-15       Impact factor: 0.751

9.  Short-term effects of 308-nm xenon-chloride excimer laser and narrow-band ultraviolet B in the treatment of vitiligo: a comparative study.

Authors:  Seok-Beom Hong; Hyun-Ho Park; Mu-Hyoung Lee
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

Review 10.  [Psoriasis vulgaris. An indication for lasers?].

Authors:  Ch Raulin; H Grema
Journal:  Hautarzt       Date:  2003-02-19       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.